Kenya bans HIV drug

Kenya bans HIV drug


James Macharia
Kenya’s Health Minister

The Kenyan Health ministry has directed officials across the country to stop prescribing a HIV drug linked to birth defects in HIV-positive women.

The directive signed by the Director of Medical Services Jackson Kioko, urged county health directors to ensure that pregnant and breastfeeding mothers to whom a front-line drug, dolutegravir (DTG), has been prescribed, continue their current prescription until they stop breastfeeding.

But those of child bearing age between 15 and 49 years, who are on the drug, should be given the first-line treatment Efavirenz.

In a memo to county directors of health, Dr Kioko said the drug, which was launched in the Kenyan market last year, was not recommended for pregnant and breastfeeding women “due to limited safety data”.

He, however, added that through a circular in June 2017, the ministry had recommended the use of DTG in alternative regimen for people with HIV and have intolerance to Efavirenz, people who inject drugs and are on anti-retroviral therapy or new patients in the same category.

– Daily Nation

About author

You might also like

Nigeria records highest ever COVID-19 infections

1,354 cases on Tuesday January 5 Nigeria has recorded 1,354 new infections of the deadly coronavirus, COVID-19, the Nigeria Centre for Disease Control, NCDC, disclosed on its verified website on

BREAKING NEWS 0 Comments

World Cancer Day: For Nigeria, Ignorance remains obstacle to control

Few people aware that early detection could save life Doctors need retraining about cancer No sustainable cancer prevention programme Nigeria joined the rest of the world Saturday to mark the

Nigeria needs documented policy for mental health – Owoeye

Prevalence: 1 in 4 individuals 20 million attempted suicide annually associated with mental health Managing Director, Psychiatric Hospital, Yaba, Dr Olugbenga Owoeye has said that Nigeria needs a documented mental

0 Comments

No Comments Yet!

You can be first to comment this post!

Leave a Reply